Shanghai confirms it's mulling a rival bid for Stada Arzneimittel

18 May 2017

Chinese drugmaker Shanghai Pharmaceutical (601607.SS) has confirmed media reports that it is in discussions with financial investors over a possible bid for German generics drugmaker Stada Arzneimittel (SAZ: Xetra).

The firm, which has a market value of $9 billion, added that that there were "a lot of uncertainties" in connection with the offer, saying that earlier reports of a bid of 70 euros ($78) per share were not true.

The Stada board recently indicated it was happy with an offer of 5.3 billion euros ($5.9 billion) to be bought by private-equity companies Bain Capital, from the USA, and London-based Cinven.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK